Latest Insider Transactions at Catalent, Inc. (CTLT)
This section provides a real-time view of insider transactions for Catalent, Inc. (CTLT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Catalent, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Catalent, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 04
2021
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Open market or private sale
|
Direct |
16
-0.04%
|
$1,664
$104.42 P/Share
|
|
Jan 04
2021
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
189
-0.26%
|
$19,656
$104.42 P/Share
|
|
Jan 04
2021
|
Karen Flynn Director |
SELL
Open market or private sale
|
Direct |
99
-0.27%
|
$10,296
$104.42 P/Share
|
|
Jan 04
2021
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
110
-0.21%
|
$11,440
$104.42 P/Share
|
|
Jan 04
2021
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
126
-0.73%
|
$13,104
$104.42 P/Share
|
|
Jan 04
2021
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
120
-0.72%
|
$12,480
$104.42 P/Share
|
|
Jan 04
2021
|
Wetteny Joseph SVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
172
-0.32%
|
$17,888
$104.42 P/Share
|
|
Jan 04
2021
|
Alessandro Maselli President & CEO |
SELL
Open market or private sale
|
Direct |
148
-0.75%
|
$15,392
$104.42 P/Share
|
|
Jan 04
2021
|
Ricardo Pravda Chief Transformation Officer |
SELL
Open market or private sale
|
Direct |
78
-0.56%
|
$8,112
$104.42 P/Share
|
|
Jan 04
2021
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Open market or private sale
|
Direct |
73
-0.48%
|
$7,592
$104.42 P/Share
|
|
Jan 04
2021
|
Ricci S Whitlow President, CSS |
SELL
Open market or private sale
|
Direct |
83
-2.48%
|
$8,632
$104.42 P/Share
|
|
Dec 21
2020
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
13,662
-11.51%
|
$1,393,524
$102.88 P/Share
|
|
Dec 21
2020
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,662
+10.18%
|
$409,860
$30.23 P/Share
|
|
Dec 17
2020
|
John R Chiminski Executive Chair |
SELL
Bona fide gift
|
Direct |
10,000
-5.76%
|
-
|
|
Nov 23
2020
|
Peter Zippelius Director |
SELL
Open market or private sale
|
Indirect |
5,392,280
-100.0%
|
$533,835,720
$99.26 P/Share
|
|
Nov 23
2020
|
Peter Zippelius Director |
BUY
Conversion of derivative security
|
Indirect |
5,392,280
+50.0%
|
$264,221,720
$49.54 P/Share
|
|
Nov 11
2020
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
2,425
-3.19%
|
$242,500
$100.99 P/Share
|
|
Oct 29
2020
|
Madhavan Balachandran Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+12.48%
|
-
|
|
Oct 29
2020
|
J Martin Carroll |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+10.5%
|
-
|
|
Oct 29
2020
|
John J Greisch Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+15.79%
|
-
|
|
Oct 29
2020
|
Rolf A Classon |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+6.46%
|
-
|
|
Oct 29
2020
|
Christa Kreuzburg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+19.51%
|
-
|
|
Oct 29
2020
|
Rosemary A Crane Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+15.79%
|
-
|
|
Oct 29
2020
|
Donald E Morel Jr |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+3.86%
|
-
|
|
Oct 29
2020
|
Gregory T Lucier |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+9.73%
|
-
|
|
Oct 29
2020
|
Jack L Stahl |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+6.46%
|
-
|
|
Oct 29
2020
|
Peter Zippelius Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+24.85%
|
-
|
|
Oct 28
2020
|
Ricardo Pravda Chief Transformation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,249
+13.89%
|
-
|
|
Oct 23
2020
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Payment of exercise price or tax liability
|
Direct |
425
-2.7%
|
$39,950
$94.02 P/Share
|
|
Oct 14
2020
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
5,510
-0.99%
|
$512,430
$93.42 P/Share
|
|
Oct 14
2020
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,515
-5.5%
|
$884,895
$93.15 P/Share
|
|
Oct 14
2020
|
Steven L Fasman EVP & Chief Admin Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,025
+7.83%
|
$420,700
$28.2 P/Share
|
|
Oct 14
2020
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Open market or private sale
|
Direct |
2,985
-4.22%
|
$277,605
$93.54 P/Share
|
|
Oct 12
2020
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
1,680
-8.9%
|
$157,920
$94.99 P/Share
|
|
Oct 07
2020
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Open market or private sale
|
Direct |
15,928
-29.2%
|
$1,449,448
$91.5 P/Share
|
|
Oct 07
2020
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Payment of exercise price or tax liability
|
Direct |
23,414
-30.03%
|
$2,130,674
$91.5 P/Share
|
|
Oct 07
2020
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
BUY
Exercise of conversion of derivative security
|
Direct |
39,342
+8.17%
|
$1,416,312
$36.28 P/Share
|
|
Oct 04
2020
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Payment of exercise price or tax liability
|
Direct |
240
-0.62%
|
$20,400
$85.88 P/Share
|
|
Oct 02
2020
|
John R Chiminski Executive Chair |
SELL
Open market or private sale
|
Direct |
182,231
-26.25%
|
$15,489,635
$85.66 P/Share
|
|
Oct 02
2020
|
John R Chiminski Executive Chair |
SELL
Payment of exercise price or tax liability
|
Direct |
86,251
-10.86%
|
$7,417,586
$86.01 P/Share
|
|
Oct 02
2020
|
John R Chiminski Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
138,135
+14.48%
|
$3,867,780
$28.2 P/Share
|
|
Oct 02
2020
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
4,359
-7.3%
|
$370,515
$85.65 P/Share
|
|
Oct 02
2020
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
5,200
-19.81%
|
$436,800
$84.94 P/Share
|
|
Oct 02
2020
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
7,347
+21.87%
|
$264,492
$36.02 P/Share
|
|
Jan 13
2020
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
1,680
-12.61%
|
$97,440
$58.0 P/Share
|
|
Dec 20
2019
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
2,406
-15.29%
|
$134,736
$56.0 P/Share
|
|
Dec 19
2019
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
1,846
-10.5%
|
$99,684
$54.0 P/Share
|
|
Sep 09
2016
|
Blackstone Management Associates V L.L.C. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
17,100,705
-100.0%
|
$393,316,215
$23.58 P/Share
|
|
Jun 09
2016
|
Blackstone Management Associates V L.L.C. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,785,539
-33.94%
|
$210,852,936
$24.51 P/Share
|
|
Jun 11
2015
|
Blackstone Management Associates V L.L.C. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,844,963
-6.65%
|
$51,658,964
$28.13 P/Share
|